EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors

In the EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28% (hazard ratio 0.72; 95% confidence interval 0.64–0.82; P < .0001) in a diverse population of over 6000 chronic kidney disease (CKD) patients, of whom >50% w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Fernandez, Beatriz, Sarafidis, Pantelis, Soler, Maria José, Ortiz, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Editorial Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387399/
https://www.ncbi.nlm.nih.gov/pubmed/37529652
http://dx.doi.org/10.1093/ckj/sfad082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387399/
https://www.ncbi.nlm.nih.gov/pubmed/37529652
http://dx.doi.org/10.1093/ckj/sfad082

Ejemplares similares